Brief: SciClone Expects FY Unaudited Profit Attributable Of At Least RMB915 Mln
25/02/2022 24:03
Feb 25 (Reuters) - SciClone Pharmaceuticals (Holdings) Ltd
6600.HK :
* SEES UNAUDITED PROFIT ATTRIBUTABLE NOT LESS THAN RMB915
MILLION
FOR FY2021
* EXPECTED RESULT PRIMARILY DUE TO SALES OF ZADAXIN,
COMMERCIAL
LAUNCH OF IN-LICENSED PRODUCTS
Further company coverage: 6600.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SciClone Pharmaceuticals (Holdings)
See all newsOneRobotics surges on plan to buy more shares
Brief: Onerobotics (Shenzhen) To Procure Affiliate Of Co To Acquire 59.9% Stake Of Nanoleaf Limited, Others
Brief: OneRobotics (Shenzhen) Says Final Offer Price Under Global Offering Is HK$73.80 Per H Share
Brief: Sciclone Pharmaceuticals (Holdings) Announces Proposal For Privatisation Of Co By Silver Pegasus Investment
Brief: SciClone Pharmaceuticals Says Trading In Shares Halted